Don’t buy all the Fed-fueled hype. The next Federal Reserve meeting is next week. It should be a complete non-event. Based on interest rate futures pricing, there is a 1-in-25 chance the Fed will raise short-term interest rates. With odds like that, any other move would spook the markets and stocks, bonds, and gold would…
DetailsThe buyout rumors are heating up. After the FDA granted approval for ACAD’s Parkinson’s disease Psychosis (PDP) treatment, the list of potential acquirers is getting longer. Not only is Pfizer, Biotgen, and Teva reportedly interested in the company, but now reports are surfacing that AstraZeneca may be a potential bidder, too. Sources say ACADIA may…
DetailsAs the U.S. economy slows, we would expect to see evidence of this in unemployment numbers, which is exactly what we’re seeing. In fact, new evidence proves the economy is not on the mend, as hoped. In May, the economy added just 38,000 jobs – the weakest showing in six years and far short of…
DetailsYesterday’s employment report was awful. The Bureau of Labor Statistics said 38,000 jobs were added in May. Wall Street was expecting 168,000. A miss by any measure. There was some good news though. The “official” unemployment rate dropped 0.3% to 4.7% and should finally have lost all remaining credibility. Normally, we’d say this is just…
DetailsDo you own any gold stocks? Are you considering taking the recent correction as a chance to take some profits? Or as a second chance to jump on? Either way, you’ve got to see this chart to understand the position gold stocks are in right now and whether they’re for you at all.
DetailsOver the last year, The Cheap Investor made a recommendation to buy Galena Biopharma (GALE) at just $1.33 in June 2015, and again at $1.67 in August 2015. As of today, the stock last traded at $2.29 for potential gains of 37% and 80%. The stock is tracking even higher after the FDA designated its…
DetailsIt’s become one of the best stocks to own over the last seven months. At just $1.75 a share, Celator Pharmaceuticals (CPXX) wasn’t considered anything special. Except for the fact it truly was…and is… Largely ignored by analysts and investors for years, we found value, recommending it in the November 2015 issue of The Cheap…
DetailsIn the November 2015 issue of The Cheap Investor, we made a recommendation to pick up shares of CPXX at just $1.75 a share. Just months later, the stock skyrocketed to a high of $17.69 for potential gains of 911% on news of successful Phase III clinical results for VYXEOS for patients with high risk…
DetailsThere aren’t too many sure things…especially in 2016. One sure thing, however, has been increasing in value over the last 20 years with far better consistency than any other asset class. It’s been less volatile than stocks, gold, real estate, and even bonds. Yet it has far surpassed them in value growth too. Looking at…
DetailsAfter hitting a high of $144.32 in 2008, oil plummeted 82% to a low of $26.05. At the time, supply significantly outweighed demand. Storage levels in Cushing, Oklahoma were nearing full capacity increasing concerns the price of oil could come under intense pressure. Millions of barrels of oil sat off the coast of the…
DetailsIt’s the biggest story in finance. The Federal Reserve is warning a rate hike is coming. Maybe in a few weeks. Maybe in a few months. But soon. And definitely by the end of the year. It has a lot of investors very worried. I’ve found a chart that says this pending rate hike should…
DetailsAs we near the June 2016 ASCO event in Chicago, Illinois, immunotherapy has again t taken center stage… especially as the FDA approves a treatment to help battle an advanced form of bladder cancer, know as urotherial carcinoma. Developed by Genentech, the treatment works by strengthening the body’s own immune, training it to attack bladder…
Details